Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Ph 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Safety and Immunogenicity Study of Adenoviral-vector Based Oral Norovirus Vaccines Expressing GI.1 or GII.4 VP1 With Monovalent or Bivalent Dosing

Trial Profile

A Ph 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Safety and Immunogenicity Study of Adenoviral-vector Based Oral Norovirus Vaccines Expressing GI.1 or GII.4 VP1 With Monovalent or Bivalent Dosing

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bivalent Norovirus vaccine-Vaxart (Primary) ; VXA G1.1 NN (Primary) ; VXA G2.4 NS (Primary)
  • Indications Norovirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Vaxart
  • Most Recent Events

    • 01 Oct 2019 Status changed from active, no longer recruiting to completed, according to a Vaxart media release.
    • 01 Oct 2019 According to a Vaxart media release, data from the study will be presented at IDWeek 2019, 7th International Calicivirus Conference 2019 and 10th International Vaccines for Enteric Diseases Conference (VED 2019).
    • 25 Sep 2019 Topline results presented in a Vaxart media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top